Clinical Trial Search

Primary: Acute Toxicity Rate — 6 percentage of participants

Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events

Primary: Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). — 70 Gray (Gy)

Primary: Participant Responses — 2; 8; 4; 6 participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months

Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients

Primary: Evaluate Patients With Progression Free Survival (PFS) — 26 months

Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…

Primary: Tumor Response Type: CR, PR, SD or PD — 1; 4; 9; 6 Participants

Primary: Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab — 0; 0; 0; 0 Participants

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Overall Survival Rate

Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy

Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019

Primary: PFS — 29.8 Months

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Time to Progression

Primary: Time to Progression (TTP)

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Objective Tumor Response — 21; 32; 17; 1 participants

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: Overall Survival — 32 months